Oral nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN) do one thing dependably: taken by mouth, they raise NAD+ in the blood, dose-dependently, across several randomized trials. Whether that raised marker changes how a person feels, performs, or ages is unsettled. The human trials on muscle strength, glucose control, and aging markers come back mostly small, mixed, or null, even where the same compounds do striking things in aged mice.
So raising NAD+ is established; that topping it up extends human healthspan or lifespan is not. This page places each claim where the evidence puts it, covers the FDA status of NMN and the short-term safety record, and explains how a daily capsule differs from an intravenous NAD+ drip.
Findings & Outcomes
What It Is
NAD+ (nicotinamide adenine dinucleotide) is a coenzyme every cell uses to turn food into usable energy and to run its repair and signaling enzymes. Its level tends to drift down with age across tissues, and that decline is the rationale behind this whole category. NMN and NR are two precursor molecules the body converts into NAD+, sold as capsules or powder for people who want to top that pool back up. Both are relatives of vitamin B3. The body already makes NAD+ from the niacin and nicotinamide in ordinary food; NR and NMN are forms that raise NAD+ more than a standard dietary intake does.
How It Works
NAD+ powers the enzymes of energy metabolism and feeds repair systems such as the sirtuins and PARPs. Its level falls with age, and NR and NMN raise it back up. Those first steps are established. The last one is not: raising the marker has not been shown to change how a person feels, performs, or ages.
Anatomy of the Practice
1The rationale: NAD+ falls with age
NAD+ is central to energy metabolism and cellular repair, and its levels decline with age in many tissues. That decline is why the precursor category exists: the hope is that restoring NAD+ toward a younger level restores some of what falls with it. The decline itself is well described. Whether reversing it reverses anything downstream is the open question.
2What the precursors do in the blood
Taken by mouth, NR and NMN are absorbed and converted into NAD+, and human trials consistently measure a rise in blood NAD+ and its metabolites within weeks. This is the dependable, replicated part. The marker rises, and it rises in a dose-related way, a pharmacological effect that is not in dispute.
3From a marker to an outcome
Raising a number on a lab report is not the same as changing how a person feels, performs, or ages. NAD+ can rise in the blood while strength, insulin sensitivity, and aging markers stay where they were. Whether the higher NAD+ reaches the tissues that matter and does useful work there is what the functional trials have to settle, and so far they mostly have not.
The same limit applies to the intravenous NAD+ drip: raising NAD+ on a lab report is not the same as lifting a function that was already running normally, and the drip has even less controlled outcome evidence than the capsules. For the biology this category aims at, see the biology of aging and the mitochondria NAD+ helps power.
What It Does
People buy a daily capsule on a simple picture: NAD+ falls with age, precursors raise it, and raising it should slow aging. That picture rests on animal work, and the animal work is the strong part. In aged mice, restoring NAD+ improves metabolism, muscle, and healthspan, and this field holds some of the more reproducible results in aging biology.
The human evidence sorts into tiers, and the cards below run in that order. The pharmacology is solid: NR and NMN raise blood NAD+ dependably and dose-dependently. The pooled functional trials are the weak point, and they speak to why people buy these compounds; added up, the precursors have not moved glucose, lipids, or muscle strength in ordinary adults over 60. Between the solid marker and the null outcomes sit two preliminary leads in narrow groups. Above everything sits a claim with no completed human trial behind it: that these precursors extend healthspan or lifespan.
How strong a result is and whether it argues for taking these are two separate questions. The best-established effect here, a raised NAD+ level, is not by itself a reason to buy a bottle.
The Research & Studies
Everything here is based on the research we have collected and checked, sorted into groups and ordered with the strongest evidence first. Click any claim to open the studies behind it.
How it works
Oral NR and NMN reliably raise blood NAD+, dose-dependently (NMN tested at 300 to 900 mg a day)
Taking NR or NMN by mouth reliably raises the level of NAD+ in the blood. This is the one effect the human evidence is solid about.
In a 2x6-week randomized double-blind crossover trial (Martens et al. 2018, Nat Commun), chronic NR supplementation in healthy middle-aged and older adults was well tolerated and effectively stimulated NAD+ metabolism. First-in-human pharmacokinetics (Trammell et al. 2016, Nat Commun) showed single oral NR doses raised the blood NAD+ metabolome dose-dependently. A dose-ranging NMN trial (Yi et al. 2023, GeroScience) found blood NAD+ rose significantly at 300, 600 and 900 mg/day versus placebo and baseline, highest at the two higher doses.
Who this may not transfer to:The rise in blood NAD+ is measured in both sexes across NR and NMN trials; it is a pharmacodynamic marker, so it does not by itself transfer to any clinical benefit.
The studies · 3
Martens et al. 2018, Nat Commun (NR elevates NAD+ in middle-aged and older adults) · Nat Commun
Trammell et al. 2016, Nat Commun (NR orally bioavailable in mice and humans) · Nat Commun
Yi et al. 2023, GeroScience (dose-dependent NMN trial) · GeroScience
NAD+ falls with age, the premise for supplementing, though restoring it has not been shown to reverse aging
NAD+ tends to fall as we get older, which is the reason people take precursors to top it up. The decline is well described; whether reversing it helps is a separate question.
Reviews of NAD+ biology (Lautrup et al. 2019, Cell Metab) describe an age-related decline in NAD+ across tissues, with downstream effects on sirtuin and PARP activity, DNA repair and mitochondrial function. This decline is the mechanistic premise for NAD+ precursor use; the review frames restoration as a hypothesis to be tested rather than an established anti-aging intervention.
Who this may not transfer to:The age-related NAD+ decline is described across tissues in both sexes; it is a biological rationale, not a population outcome.
The study · 1
Lautrup et al. 2019, Cell Metab (NAD+ in brain aging and neurodegeneration) · Cell Metab
Blood Sugar
Pooled across 8 trials in 342 adults, NMN did not move glucose, insulin, HbA1c or lipids
When all the NMN trials are added up, it did not lower blood sugar, insulin or cholesterol on average. The general metabolic benefit people expect did not appear.
A systematic review and meta-analysis (Chen et al. 2024, Curr Diab Rep) pooled eight RCTs totaling 342 middle-aged and older adults, 49% female and mainly non-diabetic, with NMN doses of 250 to 2000 mg/day over 14 days to 12 weeks. Random-effects meta-analyzes found no significant benefit on fasting glucose, fasting insulin, glycated hemoglobin, HOMA-IR or lipid profile.
Who this may not transfer to:The pooled null was in mostly non-diabetic middle-aged and older adults of both sexes, so it does not rule out an effect in metabolically impaired groups.
The study · 1
Chen et al. 2024, Curr Diab Rep (NMN on glucose and lipid metabolism meta-analysis) · Curr Diab Rep
NMN 250 mg a day for 10 weeks raised muscle insulin sensitivity in 25 prediabetic postmenopausal women
In postmenopausal women with prediabetes, ten weeks of NMN improved how well their muscle responded to insulin. It is one small trial in a specific group.
A 10-week randomized double-blind placebo-controlled trial (Yoshino et al. 2021, Science; n=25) in overweight or obese postmenopausal women with prediabetes found NMN 250 mg/day increased insulin-stimulated glucose disposal measured by clamp, raised muscle AKT and mTOR phosphorylation, and up-regulated muscle remodeling genes. Body weight, other metabolic measures and circulating markers were largely unchanged.
Who this may not transfer to:The trial enrolled only postmenopausal women with prediabetes; whether the muscle insulin-sensitivity effect transfers to men, to premenopausal women or to metabolically healthy people has not been tested.
The study · 1
Yoshino et al. 2021, Science (NMN increases muscle insulin sensitivity in prediabetic women) · Science
Muscle And Strength
Neither NMN nor NR improved muscle mass, grip strength or gait speed in adults over 60
Adding up the trials, NMN and NR did not improve muscle size, grip strength or walking speed in older adults. The strength and function claims did not hold up.
A systematic review and meta-analysis (Prokopidis et al. 2025, J Cachexia Sarcopenia Muscle) of RCTs in adults with mean age 60.9 to 83 found NMN had no significant effect on skeletal muscle index, handgrip strength, gait speed or the five-time chair-stand test, and narrative synthesis showed no benefit for knee-extension strength, SPPB or thigh muscle mass. NR was associated with a longer six-minute walk only in people with peripheral artery disease. The authors concluded current evidence does not support NMN or NR for preserving muscle mass and function.
Who this may not transfer to:The null applies to older adults of both sexes with mean age over 60; it does not address younger or athletic people.
The study · 1
Prokopidis et al. 2025, J Cachexia Sarcopenia Muscle (NMN and NR on muscle mass and function meta-analysis) · J Cachexia Sarcopenia Muscle
Counts once: this finding and 1 other here come from the same source, so they are one body of evidence, not separate confirmations.
Longevity And Mortality
No human trial has shown NAD+ precursors extend healthspan or lifespan; the striking results are in animals
The striking lifespan results are in animals. In people, no trial has shown these precursors slow aging or extend life.
A systematic review of NAD+ precursor trials (Gindri et al. 2024) catalogued outcomes across clinical conditions and identified no lifespan or aging endpoints, and a muscle meta-analysis (Prokopidis et al. 2025) found no functional benefit in older adults. The animal literature shows NAD+ restoration improving healthspan and, for related interventions, lifespan, but this has not translated to demonstrated human healthspan or lifespan benefit.
Who this may not transfer to:No human healthspan or lifespan endpoint has been measured in either sex; the extension results are in animals only.
The studies · 2
Gindri et al. 2024, Am J Physiol Endocrinol Metab (safety and effectiveness of NAD systematic review) · Am J Physiol Endocrinol Metab
Prokopidis et al. 2025, J Cachexia Sarcopenia Muscle (NMN and NR on muscle mass and function meta-analysis) · J Cachexia Sarcopenia Muscle
Counts once: this finding and 1 other here come from the same source, so they are one body of evidence, not separate confirmations.
Cardiorespiratory Fitness
NMN 600 to 1200 mg a day lifted sub-maximal aerobic capacity in 48 runners, while VO2max did not change
In amateur runners who kept training, higher NMN doses improved their sub-maximal aerobic capacity, though their peak capacity did not change.
A six-week four-arm randomized double-blind trial (Liao et al. 2021, J Int Soc Sports Nutr; n=48, 40 men and 8 women) in recreationally trained runners found the medium (600 mg) and high (1200 mg) NMN groups improved oxygen uptake, percentage of VO2max, and power at first and second ventilatory thresholds more than placebo. VO2max, O2-pulse, VO2 relative to work rate and peak power were unchanged. The authors attributed the effect to enhanced skeletal-muscle oxygen utilization.
Who this may not transfer to:The trial ran in young and middle-aged recreationally trained runners, only 8 of 48 women, so transfer to untrained or older people is untested.
The study · 1
Liao et al. 2021, J Int Soc Sports Nutr (NMN and aerobic capacity in amateur runners) · J Int Soc Sports Nutr
Getting NAD+ Up, in Order
Ways to Do It
Match what you do to what you want. If the goal is the healthspan the animal work points at, the levers with human evidence are free and come first. If the goal is to raise NAD+ specifically, the precursors do that, though what it buys you is not established. The higher rungs are a conversation to have with a clinician before you start.
Regular exercise and not eating to excess are the interventions that most reliably support NAD+ and mitochondrial health in people, and they carry decades of human evidence for healthspan that the capsules lack. If the reason you are drawn to NAD+ precursors is slower aging, this rung is the fair first answer and the one most likely to deliver.
The body makes NAD+ from vitamin B3 in ordinary food: fish, poultry, meat, mushrooms, peanuts, and fortified grains all supply niacin and nicotinamide. Outright NAD+ shortage from diet is uncommon on a mixed diet, so for most people the base of the pool is already covered without any supplement.
Nicotinamide (niacinamide) is a cheap, long-used form of vitamin B3 that also feeds NAD+. It does not raise NAD+ as much as NR or NMN, and it is not sold as anti-aging. If the aim is simply to cover B3 at low cost, it does that, and it has the longest safety record of any form here.
NR is the precursor with the most human pharmacology behind it and a clearer regulatory footing in the United States, where it is an accepted dietary ingredient. Trial doses run around 250 to 1000 mg a day. Be clear about what you are buying: it will raise your NAD+, and the functional benefits beyond that are not established. Prefer a product carrying an independent testing mark such as NSF or Informed Choice.
NMN raises NAD+ as well, and it carries the two most interesting human leads, insulin sensitivity in prediabetic women and aerobic capacity in runners. Its regulatory status in the United States is unsettled: the FDA has taken the position that NMN is excluded from the dietary-supplement definition because it was studied as a drug first, so it sits in a gray zone even though it is widely sold. Doses in trials run about 250 to 900 mg a day.
If your interest is glucose control or a diagnosed metabolic problem, the one clean positive trial was in prediabetic postmenopausal women, and that is a decision to make with the clinician who tracks your numbers. A precursor is at most an add-on to the diet, movement, and medication that manage metabolic health, and the pooled trials did not find an average glucose benefit.
Go Deeper
- IV therapy and NAD+: the intravenous version of this same idea, why an infusion is slow and costly, and how it compares with a daily oral precursor.
- The biology of aging: where NAD+ decline sits among the drivers of aging, and how to read a biomarker that moves against an outcome that may not.
- Rapamycin: the other longevity frontier where the animal record is strong and the human aging evidence is early, with the same animal-to-human gap.
- Mitochondria: the cellular power plants NAD+ helps run, and the reason energy is the mechanism most people have in mind for these precursors.
The Chinese Medicine View
NAD+ and its precursors are products of twentieth-century biochemistry, isolated and synthesized in the laboratory, so there is no entry for them in the classical Chinese pharmacopoeia. No historical text assigns a channel, a temperature, or a flavor to NMN or NR, and reading one back into them would be an invention. What the tradition offers instead is a way of thinking about aging and about building the body up, laid over the modern compound as interpretation and held apart from the trial data above.
The territory these precursors aim at, the slow thinning of the body reserves with age, is one Chinese medicine has always reasoned about, chiefly through the idea of the Kidney essence, the deep constitutional reserve it associates with growth, aging, and vitality. The tradition holds that this reserve is largely fixed at birth and spent over a lifetime, and that it can be conserved and supported but not simply refilled from a bottle. That instinct sits close to what the evidence shows: the marker can be raised, but whether the underlying reserve is actually restored is exactly the question the human trials have not answered.
Tonifying, bu, is the family of methods for building up a true deficiency, and its whole art is judging whether a deficiency is present and whether the person can transform what is given. Pouring in more than the system can use, in that framing, does not build reserve; it creates stagnation, which resembles a raised NAD+ level the tissues have not been shown to put to work. The two views meet on two points: restraint, and the person in front of you. A tradition that treats the cultivation of life, Yang Sheng, as moderation, movement, and the conserving of reserves would not hand everyone the same daily capsule any more than it hands everyone the same herb. That is offered as a way of thinking, not as a claim that Chinese medicine anticipated NAD+ biology, which it did not.
Cautions For This Practice
Extra restraintEverything to be aware of is here, in one place. This practice suits most healthy people; a few situations call for real care.
Well tolerated for weeks to months across 489 people, with only mild effects; longer use unstudied
A systematic review of NAD+ and NADH randomized trials across clinical conditions (Gindri et al. 2024, Am J Physiol Endocrinol Metab; 10 studies, 489 participants) found supplementation was well tolerated with a low incidence of side effects, the most common being muscle pain, headache, fatigue and sleep disturbance, and no serious health risks. Dedicated trials of NR (Martens et al. 2018) and NMN (Yi et al. 2023) likewise reported good tolerability over their study windows.Gindri et al. 2024, Am J Physiol Endocrinol Metab (safety and effectiveness of NAD systematic review)Martens et al. 2018, Nat Commun (NR well-tolerated)
The aging payoff is an animal result, so treat anti-aging use as experimental
The lifespan and healthspan results are in mice. In people, no completed trial has shown that raising NAD+ with a precursor slows aging. Taking NMN or NR in the hope of living longer is an experiment on yourself with an effect no human trial has measured, and a reason not to let a capsule displace the exercise and eating habits that do have human healthspan evidence.
Short-term safety looks good, long-term is unstudied
Across the human trials, NR and NMN have been well tolerated for weeks to a few months, with mostly mild effects such as nausea, headache, or fatigue and no serious adverse events reported. What is missing is the long run: these compounds have not been studied over years, which is the timescale anyone taking them for aging has in mind. Well tolerated so far is not the same as known to be safe indefinitely.
A theoretical concern with cancer, still unresolved
NAD+ fuels the growth and repair machinery of all cells, including cancerous ones, and some laboratory work raises the question of whether pushing NAD+ up could feed an existing tumor. This has not been shown to happen in people and remains a theoretical concern, but it is a reason for anyone with a current or recent cancer to raise NAD+ precursors with their oncologist before starting.
NMN sits in a regulatory gray zone
In the United States the FDA has taken the position that NMN is excluded from the dietary-supplement definition, because it was authorized for study as a drug before it was marketed as a supplement. It is nonetheless widely sold, and enforcement has been inconsistent. This does not make NMN dangerous, but it does mean the usual supplement oversight is uncertain, which raises the value of choosing a product with independent third-party testing.
Kidney or liver disease, pregnancy, and medication overlap
These precursors are processed and cleared by the body like other nutrients, and the trials showing they are tolerated were mostly in reasonably healthy adults. If you have kidney or liver disease, are pregnant or breastfeeding, or take medication for a metabolic condition, raise it with your clinician before starting, since supplemental doses in those situations have not been well studied.
Buy tested, and keep the dose in the studied range
Supplements are loosely regulated, so a product carrying an independent testing mark such as NSF or Informed Choice is the simplest way to know the label matches the contents, which matters more for NMN given its unsettled status. The human trials sit at roughly 250 to 1000 mg a day; there is no established reason to go above that, and more is not known to be better.
Start slow, be smart, read the research, and consult a professional if you have any concerns. This is here to inform your choice, not make it for you.
Common Questions
Do NMN and NR actually work?
It depends what you mean by work. They do one thing reliably: taken by mouth, both raise NAD+ in the blood, shown across several randomized trials, and that part is settled. The benefits people buy them for are a different matter. When the human trials are pooled, NMN did not improve glucose or lipid metabolism on average, and neither precursor preserved muscle mass or strength in older adults. A few specific leads look promising, but the general payoff is not established, and raising the marker has not reliably delivered the outcomes.
Will taking NAD+ precursors make me live longer?
That is not shown in people. The lifespan and healthspan results come from mice, a species where many interventions extend life without ever repeating in humans. The human work so far measures blood NAD+, metabolic markers, and physical function over weeks or months, not years of life, and no completed trial has tested whether these precursors slow human aging. The accurate summary is a strong animal record, a reliably raised marker, and a longevity benefit that stays an open question.
What is the difference between NMN and NR?
Both are NAD+ precursors and both raise blood NAD+. NR has the longer run of human pharmacology behind it and a clearer regulatory footing in the United States, where it is an accepted dietary ingredient. NMN carries the two most interesting human leads, on insulin sensitivity and aerobic capacity, but its regulatory status is unsettled because the FDA treats it as excluded from the supplement definition. For raising NAD+ they are broadly comparable; the differences are mostly in evidence base and legal standing, and neither has a demonstrated advantage over the other.
Is an NAD+ pill the same as an NAD+ IV drip?
No, and the oral route is usually the more sensible one. A daily capsule of NR or NMN is cheap and raises NAD+ steadily over weeks, whereas an intravenous NAD+ drip is slow, expensive, and has even less controlled outcome evidence behind it. Both share the same limit: they raise the marker, and whether that changes how you feel or age is not established. If the goal is simply higher NAD+, the pill does that at a fraction of the cost and hassle of the drip.
Are NMN and NR safe?
For the timescales studied, they have been well tolerated. Human trials of weeks to a few months report mostly mild effects, such as nausea or headache, and no serious adverse events. Two things temper that. Long-term use over years has not been studied, which is the timescale anti-aging use implies, and because NAD+ fuels cell growth there is an unresolved theoretical question about existing cancers. People with kidney or liver disease, women who are pregnant or breastfeeding, and anyone on medication for a metabolic condition should check with a clinician first.
Explore Related
Other pages this one connects to, by the evidence they share, the outcomes they touch, and the ground they cover.
All 12 sources on this page independently checked and cross-referenced.
Thomas Dehli, Founder & Editor, Sacred Lotus
Sacred Lotus has published Chinese medicine reference material since 2001. Integrative pages are held to the same standard as the herb and formula library: cite the source, grade the claim at its real strength, and say where the research has not looked. This page is educational and it is not medical advice. Last reviewed and updated August 9, 2026.
Evidence strength
How confidently the research supports a claim. Strength describes the evidence, not our endorsement.